Celldex vaccine improves long-term brain cancer survival in study
Amazing results. 25% of patients with recurrent gbm alive after 2 years compared with NONE in the control group! The FDA should try to get this approved as soon as possible. We shouldn't have to wait years for another study.
IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source: http://www.reuters.com/article/2015/11/20/us-celldex-glioblastoma-idUSKCN0T92OS20151120#PC7DDDj8iG87sZyq.97
(Everything below this line is from VirtualTrials.com!)
Click HERE to return to brain tumor news headlines